C:\STNEXP4\QUERIES\09191199.str





```
chain nodes :
    15  19
ring nodes :
    1  2  3  4  5  6  7  8  9  10  11  12  13  14
chain bonds :
    7-15  8-19  11-15
ring bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  10-11  10-14  11-12
    12-13  13-14
exact/norm bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  7-15  8-9  8-19  10-11
    10-14  11-12  11-15  12-13  13-14


G1:C,N

G2:O,S,N

Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom
    10:Atom  11:Atom  12:Atom  13:Atom  14:Atom  15:CLASS  19:Atom
```

```
=> d his

     (FILE 'HOME' ENTERED AT 13:13:27 ON 15 OCT 2001)

     FILE 'REGISTRY' ENTERED AT 13:14:11 ON 15 OCT 2001
L1             STRUCTURE UPLOADED
L2             QUE L1
L3         46469 S NC4-NC5/ES
L4            28 S L2  SUB=L3 FUL

     FILE 'CAPLUS' ENTERED AT 13:16:26 ON 15 OCT 2001
L5             4 S L4

=> d l2
L2 HAS NO ANSWERS
L1             STR
```



G1 C,N

G2 O,S,N

```
Structure attributes must be viewed using STN Express query preparation.
L2             QUE  ABB=ON  PLU=ON  L1


=> d bib abs hitstr l5 1-4
```

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 2001:661426 CAPLUS
DN 135:226880
TI Synthesis of Pyrolyllactone-indolinone derivatives as kinase inhibitors
IN Tang, Peng Cho; Miller, Todd A.; Li, Xiaoyuan; Zhang, Ruofei; Cui, Jingrong; Huang, Ping; Wei, Chung Chen
PA Sugen, Inc., USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064681	A2	20010907	WO 2001-US6214	20010228

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-185536 P 20000228
GI



I



II

AB Title compds. I [R1 = H, alkyl, (hetero)arom. ring, (hetero)aliph. ring, etc.; R2-5 = H, alkyl, (hetero)arom. ring, (hetero)aliph. ring; A, B, D, E = C or N provided that one or two = N and provided that when A, B, D or E = N, no R1 is attached to A, B, D or E; m = 2 - 4; q = 1 - 4] were prepd. Examples include data for over 50 compds. synthesized and over 20 bioassays (data for 4 bioassays provided). For instance, tosylmethyl isocyanide was added to 5,6-dihydro-2H-pyran-2-one (DBU, THF, 0.degree.C, room temp., 2 h.) to give 6,7-dihydro-2H-pyrano[3,4-c]pyrrol-4-one. This intermediate was formylated in the 1-position (DMF, POCl3, DCM, room temp., 1 h.) followed by condensation of the 1-formyl deriv. with 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid N-Me amide to yield II. II had IC50 = 0.005 mM for cdk2/cyclin A and IC50 = 6.64 mM for GST-Flk1. Compds. II are used to treat cancer, e.g., squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, etc.

IT **358733-07-0P 358733-08-1P 358733-09-2P**
358733-10-5P 358733-11-6P 358733-12-7P
358733-13-8P 358733-14-9P 358733-15-0P
358733-16-1P 358733-17-2P 358733-18-3P
358733-19-4P 358733-20-7P 358733-21-8P
358733-23-0P 358733-24-1P 358733-25-2P
358733-26-3P 358733-27-4P 358733-28-5P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of Pyrolyllactone-indolinone derivs. as kinase inhibitors)

RN 358733-07-0 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-08-1 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-09-2 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(6-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-10-5 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(6-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-11-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-12-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-13-8 CAPLUS
CN Pyrrolidine, 1-[[2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 358733-14-9 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 358733-15-0 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-16-1 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-17-2 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-18-3 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-19-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-20-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-21-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-23-0 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)



RN 358733-24-1 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)



RN 358733-25-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-26-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-27-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-28-5 CAPLUS
CN Pyrano[3,4-c]pyrrol-4(2H)-one, 1-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]-6,7-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 2001:472721 CAPLUS
DN 135:76886
TI Preparation of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors
IN Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho; McmMhon, Gerald; Hirth, Klaus Peter; Cui, Jingrong
PA Sugen, Inc., USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046196	A1	20010628	WO 2000-US34259	20001221

PI
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-171288 P 19991221
OS MARPAT 135:76886
GI



I

AB This invention relates to 4-substituted 7-azaindolin-2-ones I [R1 = H, Me; R2, R3 = H, halo, alkyl, alkoxy or R2R3 = methylindene or hetero ring; R4 = H, Me, CF3, etc.; X = bond, ethynyl, O, S, etc.; Y = ring; Z = N, CR6] and their use as protein kinase inhibitors. E.g., -[4-(1-benzyl-1H-indol-5-ylamino)-6-oxo-6,7-dihydropyrrolo[2,3-d]pyrimidin-5-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-ylethyl)amide hydrochloride was prepd. from 5-(4-chloro-6-oxo-6,7-dihydropyrrolo[2,3-d]pyrimidin-5-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid(2-morpholin-4-yl-ethyl)amide and 1-benzyl-1H-indol-5-ylamine.
IT **346599-64-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors)
RN 346599-64-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-[[4-[(3-chloro-4-fluorophenyl)amino]-1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]-4-methyl-N-[2-(4-

morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **346600-27-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors)

RN 346600-27-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-[(4-chloro-1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 4
RE
(1) Cockerill, G; WO 9802438 A 1998 CAPLUS
(2) Glaxo Group Ltd; WO 9921859 A 1999 CAPLUS
(3) Longo, A; US 5719135 A 1998 CAPLUS
(4) Upjohn Co; WO 9320078 A 1993 CAPLUS

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 2000:117197 CAPLUS
DN 132:166123
TI 3-Methylidenyl-2-indolinone modulators of protein kinase
IN Tang, Peng Cho; Sun, Li; Miller, Todd Anthony; Liang, Congxin; Tran, Ngoc My; Nguyen, Anh Thi; Nematalla, Asaad
PA Sugen, Inc., USA
SO PCT Int. Appl., 347 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000008202	A2	20000217	WO 1999-US17845	19990804
	WO 2000008202	A3	20000518		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9954684	A1	20000228	AU 1999-54684	19990804
PRAI	US 1998-129256	A	19980804		
	US 1998-95470	P	19980805		
	US 1998-102178	P	19980928		
	US 1999-116107	P	19990115		
	WO 1999-US17845	W	19990804		

OS MARPAT 132:166123
GI



I



II

AB The title compds. (I) [wherein A = C or N; Q = substituted Ph, pyrrolyl, or indolyl; R0 = H, alkyl, C(O)R19, or C(O)OR19; R1 = H, (un)substituted alkyl, alkoxy, halo, aryl, (CH2)nOC(O)R19, or C(O)NR19; R2 = H, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, trihalomethyl, alkoxy, halo, sulfamido, C(O)OR19, C(O)R19, NHC(O)OR19, (un)substituted amino, etc.; R3 = H, alkyl, trihalomethyl, alkoxy, aryl(oxy), heteroaryl, heteroalicyclic, OH, halo, sulfamido, C(O)R19, (un)substituted amino, etc.; R4 = H, alkyl, alkoxy, or halo; R19 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; n = 1-4] were prepd. as modulators of the activity of receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs), and serine/threonine protein kinases (STKs). Examples include over 200 syntheses and data from seventeen bioassays. For instance, II was prepd. by a 3-step sequence involving: (1) cyclization and redn. of 2,4-dinitrophenylacetic acid with SnCl2.2H2O in EtOH to form 6-amino-2-oxindole, (2) amidation with AcCl in CH2Cl2, and (3) condensation of the amide with 3,5-diisopropyl-4-methoxybenzaldehyde. II was tested for HER-2 kinase activity (IC50 = 6.4 .mu.M), cellular proliferation activity as measured by the incorporation of bromodeoxyuridine (BrdU) driven by HER-2 (IC50 = 9.1 .mu.M) or EGF (IC50 = 11 .mu.M), and antitumor activity as measured by growth of SKOV3 ovarian carcinoma cells (IC50 = 2.6 .mu.M) or A431 human epidermoid carcinoma cells (IC50 = 2.2 .mu.M). The invention compds. are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease.

IT **258831-03-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of 3-methylidenyl-2-indolinones as protein kinase modulators for the prevention and treatment of cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease)

RN 258831-03-7 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1999:297422 CAPLUS
DN 130:325139
TI Preparation of arylmethylideneazaoxindoles as protein kinase inhibitors.
IN Cheung, Mui; Glennon, Kimberly Caroline; Lackey, Karen Elizabeth; Peel, Michael Robert
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921859	A1	19990506	WO 1998-EP6357	19981008
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9911510	A1	19990517	AU 1999-11510	19981008
PRAI	GB 1997-21437		19971010		
	WO 1998-EP6357		19981008		

OS MARPAT 130:325139
GI



I

AB Title compds. [I; R1 = (substituted) Het, aryl, biaryl; R2-R4 = H, het, fused Het, aryl, aliphatyl, cyano, NO2, halo, OR5, SR5, SOR5, NR5R7, COR5, CO2R5, NR5COR5, CONR5R7, etc.; R5 = H, halo, (substituted) Het, aryl, aliphatyl, etc.; R7 = H, R5; Het = (R5 -substituted) acridinyl, benzimidazolyl, benzofuryl, carbazolyl, dithianyl, furyl, imidazolyl, morpholinyl, naphthyridinyl, oxadiazinyl, oxathiazolyl, pyrazolyl, pyridazinyl, quinoxalinyl, tetrazinyl, thiomorpholinyl, thiopyranyl, etc.], were prepd. Thus, 5-bromo-7-azaoxindole (prepn. given), 1-(3,5-dichlorophenyl)pyrrole-2-carboxaldehyde, and 4-methylmorpholine were refluxed in PhMe for 6 h to give 64% 5-bromo-3-[1-(3,5-dichlorophenyl)-1H-pyrrol-2-ylmethylidene]-1,3-dihydropyrrolo[2,3-b]pyridin-2-one. Several I inhibited raf kinase with IC50 < 1 .mu.M.

IT **223645-86-1P 223645-93-0P 223645-94-1P**
223645-99-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylmethylideneazaoxindoles as protein kinase inhibitors)

RN 223645-86-1 CAPLUS

CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 223645-93-0 CAPLUS
CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 223645-94-1 CAPLUS
CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 3-(2-furanylmethylene)-1,3-dihydro-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 223645-99-6 CAPLUS
CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-5-(2-furanyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 1
RE
(1) Pharmacia; WO 9616964 A 1996 CAPLUS

US 091911990YP1

Creation date: 02-05-2004
Indexing Officer: KHALL - KIM HALL
Team: OIPEBackFileIndexing
Dossier: 09191199

Legal Date: 10-19-2001

No.	Doccode	Number of pages
1	CTNF	21
2	892	1
3	1449	1
4	1449	1

Total number of pages: 24

Remarks:

Order of re-scan issued on .....